Investigators conducted a retrospective study of patients treated for early-stage breast cancer at Fred Hutch Cancer Center to identify clinicopathologic factors associated with SLN-positivity (SLN+), ...

Net sales totalled EUR 939.3 (January-June 2025: 771.0) million Operating profit was EUR 291.3 (182.5) million Basic earnings per share were EUR 1.64 (1.02) Cash flow from operating activities per ...

Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...

In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.

In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, my phone kept buzzing with alerts ...

Employers increasingly steer weight-loss GLP-1 access to direct-to-consumer subscriptions, sometimes funding HSAs/FSAs instead of adding formal plan coverage. Coverage remains diabetes-centric: 60% ...

A prospective survey study presented at the 2026 ASCO Annual Meeting highlighted the heterogeneity of patient experiences ...

IQVIA projects 118 U.S. biologics losing exclusivity by 2034 (~$234B opportunity), but only 12 had biosimilars in development as of Sept 2024, leaving most molecules uncontested. FDA draft guidance ...

At the American Society of Clinical Oncology (ASCO) meeting, phase II findings suggested that intratumoral dendritic cell ...

These people shape everything from treatment availability to insurance plans and real-world results for patients.

Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s annual meeting for a weekend of buzzy data drops, practice-changing posters and ...